[ Author(Desc)] Title Type Year
Filters: Keyword is Humans  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
L
Liantonio A, De Luca A, Pierno S, Didonna MPaola, Loiodice F, Fracchiolla G, Tortorella P, Antonio L, Bonerba E, Traverso S et al..  2003.  Structural requisites of 2-(p-chlorophenoxy)propionic acid analogues for activity on native rat skeletal muscle chloride conductance and on heterologously expressed CLC-1.. Br J Pharmacol. 139(7):1255-64.
Liantonio A, Giannuzzi V, Picollo A, Babini E, Pusch M, D Camerino C.  2007.  Niflumic acid inhibits chloride conductance of rat skeletal muscle by directly inhibiting the CLC-1 channel and by increasing intracellular calcium.. Br J Pharmacol. 150(2):235-47.
Liantonio A, Pusch M, Picollo A, Guida P, De Luca A, Pierno S, Fracchiolla G, Loiodice F, Tortorella P, Camerino DConte.  2004.  Investigations of pharmacologic properties of the renal CLC-K1 chloride channel co-expressed with barttin by the use of 2-(p-Chlorophenoxy)propionic acid derivatives and other structurally unrelated chloride channels blockers.. J Am Soc Nephrol. 15(1):13-20.
Liantonio A, Accardi A, Carbonara G, Fracchiolla G, Loiodice F, Tortorella P, Traverso S, Guida P, Pierno S, De Luca A et al..  2002.  Molecular requisites for drug binding to muscle CLC-1 and renal CLC-K channel revealed by the use of phenoxy-alkyl derivatives of 2-(p-chlorophenoxy)propionic acid.. Mol Pharmacol. 62(2):265-71.
Liantonio A, Picollo A, Carbonara G, Fracchiolla G, Tortorella P, Loiodice F, Laghezza A, Babini E, Zifarelli G, Pusch M et al..  2008.  Molecular switch for CLC-K Cl- channel block/activation: optimal pharmacophoric requirements towards high-affinity ligands.. Proc Natl Acad Sci U S A. 105(4):1369-73.
Lichtman AD, Kjaer K.  2013.  Combined cesarean delivery and repair of acute ascending and aortic arch dissection at 32 weeks of pregnancy.. J Cardiothorac Vasc Anesth. 27(4):731-4.
Lichtman AD.  2003.  An unusual anterior mediastinal mass.. J Cardiothorac Vasc Anesth. 17(3):405-6.
Lichtman AD, Oribabor C.  2006.  Malignant hyperthermia following systemic rewarming after hypothermic cardiopulmonary bypass.. Anesth Analg. 102(2):372-5.
Lichtman AD, Carullo V, Minhaj M, Karkouti K.  2007.  Case 6--2007: massive intraoperative thrombosis and death after recombinant activated factor VII administration.. J Cardiothorac Vasc Anesth. 21(6):897-902.
Lien CA, Matteo RS, Ornstein E, Schwartz AE, Diaz J.  1991.  Distribution, elimination, and action of vecuronium in the elderly.. Anesth Analg. 73(1):39-42.
Lien CA, Belmont MR, Abalos A, Hass D, Savarese JJ.  1999.  The nature of spontaneous recovery from mivacurium-induced neuromuscular block.. Anesth Analg. 88(3):648-53.
Lien CA, Gadalla F, Kudlak TT, Embree PB, Sharp GJ, Savarese JJ.  1993.  The effect of ondansetron on atracurium-induced neuromuscular blockade.. J Clin Anesth. 5(5):399-403.
Lien CA, Belmont MR, Roth DLWray, Okamoto M, Abalos A, Savarese JJ.  1999.  Pharmacodynamics and the plasma concentration of mivacurium during spontaneous recovery and neostigmine-facilitated recovery.. Anesthesiology. 91(1):119-26.
Lien CA, Belmont MR, Abalos A, Eppich L, Quessy S, Abou-Donia MM, Savarese JJ.  1995.  The cardiovascular effects and histamine-releasing properties of 51W89 in patients receiving nitrous oxide/opioid/barbiturate anesthesia.. Anesthesiology. 82(5):1131-8.
Lien CA, Savard P, Belmont M, Sunaga H, Savarese JJ.  2009.  Fumarates: unique nondepolarizing neuromuscular blocking agents that are antagonized by cysteine.. J Crit Care. 24(1):50-7.
Lien CA, Hemmings HC, Belmont MR, Abalos A, Hollmann C, Kelly RE.  1996.  A comparison: the efficacy of sevoflurane-nitrous oxide or propofol-nitrous oxide for the induction and maintenance of general anesthesia.. J Clin Anesth. 8(8):639-43.
Lien CA, Schmith VD, Embree PB, Belmont MR, Wargin WA, Savarese JJ.  1994.  The pharmacokinetics and pharmacodynamics of the stereoisomers of mivacurium in patients receiving nitrous oxide/opioid/barbiturate anesthesia.. Anesthesiology. 80(6):1296-302.
Lien CA.  2011.  Development and potential clinical impairment of ultra-short-acting neuromuscular blocking agents.. Br J Anaesth. 107 Suppl 1:i60-71.
Lien CA, Schmith VD, Belmont MR, Abalos A, Kisor DF, Savarese JJ.  1996.  Pharmacokinetics of cisatracurium in patients receiving nitrous oxide/opioid/barbiturate anesthesia.. Anesthesiology. 84(2):300-8.
Lien CA, Koff H, Malhotra V, Gadalla F.  1997.  Emergence and extubation: a systematic approach.. Anesth Analg. 85(5):1177.
Lien CA.  2010.  Neostigmine: how much is necessary for patients who receive a nondepolarizing neuromuscular blocking agent? Anesthesiology. 112(1):16-8.
Lien CA, Kopman AF.  2014.  Current recommendations for monitoring depth of neuromuscular blockade.. Curr Opin Anaesthesiol. 27(6):616-22.
Lien CA.  2012.  A need to establish programs to detect and prevent drug diversion.. Mayo Clin Proc. 87(7):607-9.
Lien CA, Belmont MR, Heerdt PM.  2005.  GW280430A: pharmacodynamics and potential adverse effects.. Anesthesiology. 102(4):861-2;authorreply862-3.
Lingamaneni R, Krasowski MD, Jenkins A, Truong T, Giunta AL, Blackbeer J, MacIver MB, Harrison NL, Hemmings HC.  2001.  Anesthetic properties of 4-iodopropofol: implications for mechanisms of anesthesia.. Anesthesiology. 94(6):1050-7.